Request availability and a quotation for your required quantity and destination.
| Product | Monobenzone 20% - Benoquin Cream 30 g |
|---|---|
| Categories | Skin Care |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Catalogue category: Skin Care
Composition: Monobenzone 20%, topical cream
Product form: Topical gel or cream
Manufacturer/pack: Verify before clinical use
Benoquin contains monobenzone, a potent depigmenting agent intended for final depigmentation in extensive vitiligo under dermatologist supervision. It can cause permanent loss of pigmentation and is not a cosmetic fairness or treatment for ordinary dark spots.
Historically approved U.S. labeling restricts use to final depigmentation in disseminated vitiligo affecting more than half the body surface. Do not use for melasma, freckles, acne marks or routine skin lightening.
Monobenzone can destroy pigment-producing melanocytes, sometimes leading to permanent, irregular depigmentation beyond the application area.
Irreversible pigment loss, irritation and marked photosensitivity are major concerns. It should never be used as a substitute for hydroquinone. Specialist oversight and sun protection are necessary. U.S. regulatory records report the historic Benoquin product was discontinued, so manufacturer-specific current regulatory status must be checked.
See Cureiva’s discussion of acne and dark marks for conditions that require different treatment. Monobenzone is not suitable for cosmetic pigmentation.
Benoquin contains monobenzone, a potent depigmenting agent intended for final depigmentation in extensive vitiligo under dermatologist supervision. It can cause permanent loss of pigmentation and is not a cosmetic fairness or treatment for ordinary dark spots.
Historically approved U.S. labeling restricts use to final depigmentation in disseminated vitiligo affecting more than half the body surface. Do not use for melasma, freckles, acne marks or routine skin lightening.
Monobenzone can destroy pigment-producing melanocytes, sometimes leading to permanent, irregular depigmentation beyond the application area.
Irreversible pigment loss, irritation and marked photosensitivity are major concerns. It should never be used as a substitute for hydroquinone. Specialist oversight and sun protection are necessary. U.S. regulatory records report the historic Benoquin product was discontinued, so manufacturer-specific current regulatory status must be checked.
Do not infer safe duration or frequency from the product name; confirm the approved pack directions with a clinician.
Response varies. The underlying diagnosis and clinical follow-up determine whether treatment is helping.
Safety in pregnancy and breastfeeding requires individual professional review.
Avoid self-combining products without reviewing interactions and local irritation risks.
Persistent symptoms need re-evaluation rather than repeated unsupervised courses.
Medical assessment is needed for severe or unexpected symptoms.
Cureiva handles legitimate medicine enquiries subject to prescription rules, product verification and import restrictions. This page is educational and does not claim an independent clinician has signed off the content.